JAK2, CALR, and MPL can be seen in about 90% of MPN cases; nevertheless, in 2% of PV, 15% of ET patients, and approximately 8%–10% of MF cases, driver mutations are not detected; such patients are termed TN patients. Here, JAK2 is linked to myeloproliferative disorder.